Ograniczanie wyników

Czasopisma help
Autorzy help
Lata help
Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 39

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  szczepionki inaktywowane
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
The article discusses the essence, purposes, methods of realizing and benefits of applying DIVA (Differentiating Infected from Vaccinated Animals) strategy for the eradication of infectious diseases of animals. Various types of marker vaccines and compatible serological tests suitable for use in this strategy are characterized. The article presents possibilities, principles, results and perspectives of applying DIVA strategy to eradicate Aujeszky«s disease, infectious bovine rhinotracheitis, classical swine fever, bovine viral diarrhoea and mucosal disease, foot and mouth disease, avian influenza, porcine parvovirus infection, bluetongue, equine influenza and African horse sickness. Through the application of marker vaccines which enable differentiation between infected and vaccinated animals as well as detection of asymptomatic carriers and shedders, DIVA strategy makes it possible to rid the population of many dangerous pathogens causing epizootics and panzootics. In appreciating the considerable importance of modern marker vaccines in the comprehensive eradication programmes for infectious diseases, this strategy not only considerably reduces economic losses and restores possibilities of international trade in animals and animal products, but also constitutes an alternative to the extremely expensive and sometimes strongly criticized administrative eradication method. That is why DIVA strategy should be more and more often applied for the eradication of infectious diseases in animals, but some of its elements, concerning mainly vaccine evaluation and the monitoring of infections in vaccinated and non-vaccinated groups of people, could also be utilized in public health protection.
The aim of the study was to observe the time course of the immune response in pigeons after immunization with a live (attenuated) vaccine, Zoosal T, and an autogenous bacterin (inactivated vaccine). The tube agglutination test and the ELISA test were used to measure the dynamics of serum antibodies to Salmonella, determine the white blood cell (WBC) count, and evaluate the leukogram of immunized pigeons. In order to evaluate the cellular response in immunized birds, a leukocyte migration inhibition (LMI) procedure was developed and tested. Histological changes were determined in pigeons immunized with ZOOSAL T and the experimental vaccine. The tests revealed a relationship between the beginning of the immune response as evaluated by tube agglutination and ELISA tests and by the MIF test. After immunization with ZOOSAL T, when the cellular response, as measured by the LMI test, appeared at day 14 and amounted to 32% migration inhibition, there was also a significant increase in antibody titers in the agglutination test (70.00) and an increase in ELISA OD values (0.259). After a single administration of the experimental vaccine, the agglutination antibody titers at day 21 of the experiment increased markedly (93.33), as did ELISA OD value, which increased until day 35 (to 0.345). Leukocyte migration inhibition reached the highest value (26%) at day 28, which shows that the immune response after single immunization increased more slowly than in group B. At day 7 after repeat vaccination with the autogenous bacterin, there was a significant increase in agglutination antibody titers (320.00). Similar patterns of changes were observed in the ELISA test. High OD values appeared at day 7 after revaccination (0.985) and persisted during the subsequent days of the experiment (28 days after revaccination: OD = 0.931) The cellular response appeared as early as 24 hours after revaccination (39% migration inhibition) and increased very rapidly, reaching 76% inhibition at day 3. Subsequently, there was a slow decline, but 2 weeks after repeat vaccination, the percentage of migration inhibition was still 22% (tab. 1, 2, 5). Our study demonstrated that the experimental vaccine based on an isolated strain of Salmonella Typhimurium var. Copenhagen, containing carbomer and Ginseng extract (Radix panax ginseg), administered twice to domestic pigeons induced a humoral and cellular immune response that was twice as strong as the response induced by the commercial vaccine ZOOSAL T.
The purpose of the work was to determine the protective properties of a vaccine, called Felisvac Me, developed according to the authors’ own technology. Examinations were carried out on 33 domestic, shorthaired cats 1-6 months of age. The degree of specific immunity was evaluated by a challenge trial, contact infection (simulation of natural contagion), delayed type of hypersensitivity test and the migration inhibition test of leukocytes. It was found that the vaccine without an adjuvant in a dose of 2 ml did not fully protect one-month old cats from being infected with a virulent strain of M. canis. Cats, which were given a higher dose of the vaccine (3 ml per animal) adsorbed on aluminium hydroxide, turned out to be immune to both methods of infection by challenge trials. The vaccine elicited a delayed type of hypersensitivity that persisted on almost a similar level (0.8--1.1 mm) throughout the observation period, i.e. 5 months. Positive values (25.2-32.4%) of the leukocyte migration inhibition test - the consecutive determinant of cellular type of immunity, were found between 22 and 41 days after vaccination. The above vaccine is characterised by a high protective value; it is also safe for both animals and environment. No side effects have been observed.
Bovine respiratory syncytial virus (BRSV) is a virus of the Pneumovirus genus belonging to the subfamily Pneumovirinae of the Paramyxoviridae family. BRSV is one of the main infectious agents causing bovine diseases of the upper and lower respiratory tract, affecting mainly young animals under the age of 9 months. It is responsible for high economic losses in the cattle industry around the world. The most effective and widely used method for limiting costs of infection with BRSV is immunoprophylaxis. Till now, this subject was rarely an object of interest in Polish scientific literature, therefore the aim of this article is to present current information on the types of available vaccines, their efficiency and safety. Additionally, a description of the variability of most immunogenic regions of BRSV and it is influence on the efficiency of the commonly used vaccines is included.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.